This cooking tutorial provides step-by-step instructions on how to elevate three traditional BBQ side dishes—green beans, ...

Announced at CES 2026 for $449, the XREAL 1S brings 1,200p Micro-OLED displays with 700 nits of brightness and the X1 chip that lets you switch from 2D to 3D instantly. The optional Neo hub ($99 now, ...

Ahead of launching its first Android XR product, “Project Aura,” the new XREAL 1S glasses deliver some impressive new display upgrades, and for a lower price than its predecessor too. The XREAL 1S is ...

Posts from this topic will be added to your daily email digest and your homepage feed. Despite the spec bump, the Xreal 1S are $50 cheaper than their predecessor. Despite the spec bump, the Xreal 1S ...

XREAL has announced the XREAL 1S, a replacement for its XREAL One AR glasses. The 1S glasses come with higher-resolution displays, a wider field of view, and more improvements. XREAL also announced ...

Novo Nordisk is seeking FDA approval for an experimental obesity shot, CagriSema (cagrilintide and semaglutide), according to a Dec. 18 news release from the Denmark-based drugmaker. CagriSema is a ...

Share on Pinterest Research suggests that GLP-1 drugs likely have little to no effect on risk for obesity-related cancers. Image credit: James Manning – PA Images/Getty Images In 2022, about 2.5 ...

GLP-1 usage is on the rise, and researchers are looking for other health benefits associated with the drug, including its effects on bladder health. But as GLP-1s rise in popularity, so do nicknames ...

Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also ...

XREAL is wrapping up 2025 with the launch of a new entry-level AR glasses model, the XREAL 1S. It sits below the more expensive XREAL One Pro (announced in July) in the lineup and is the first in the ...

CHICAGO, Nov 25 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and ...